Author

Alessio Bruscaggin

Institute of Oncology ResearchORCID 0009-0004-9938-0396Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alberto J. ArribasiD· 1 shared Anastasios StathisiD· 1 shared Andrea RaimondiiD· 1 shared Andrea RinaldiiD· 1 shared Antonella ZucchettoiD· 1 shared Chiara TarantelliiD· 1 shared Davide RossiiD· 1 shared Eleonora CannasiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alberto J. ArribasORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas

Alberto J. Arribas, Eleonora Cannas, Giulio Sartori, Francesca Guidetti, Luciano Cascione, Sara Napoli, Gabriela Forestieri, Federica Fuzio, Emma Pesenti, Chiara Tarantelli, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, Alessio Bruscaggin, Andrea Rinaldi, , Francesco Bertoni

This study identifies IL-16 production as a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas, showing that targeting the IL-16/CD9 axis restores drug sensitivity.

Blood · May 29, 2026Peer-reviewedCancer Biology